SCHEMBL4834217

SCHEMBL4834217

O=C(/C=C/c1snnc1-c1ccc(F)cc1)Nc1ccc(CP(=O)(O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 2/20 0.41
MMP1 P03956 4/20 0.40
MMP2 P08253 4/20 0.40
MMP9 P14780 4/20 0.40
EGFR P00533 1/20 0.40
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
CDK19 Q9BWU1 1/20 0.39
HPSE Q9Y251 2/20 0.39
TP53 P04637 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
MAOB P27338 1/20 0.38
NAMPT P43490 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834235 1.00 SNCA (0.41) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4831233 0.89 NPC1 (0.39) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4834265 0.88 BTK (0.40) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4829380 0.84 MMP1 (0.40) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4829396 0.84 MMP1 (0.40) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4831239 0.82 MAOB (0.43) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4831227 0.82 MAOB (0.43) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4834255 0.82 MAOB (0.41) SNCAMMP1MMP2MMP9EGFR
SCHEMBL4834273 0.82 MAOB (0.41) SNCAMMP1MMP2MMP9EGFR
SCHEMBL27612956 0.79 MAOB (0.44) SNCAMMP1MMP2MMP9EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 SNCA 1545/4885MMP1 4721/4885MMP2 4741/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 SNCA 1545/4885MMP1 4721/4885MMP2 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.